X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
Under the agreement, Coya will in-license the proposed Abatacept biosimilar for the development of Coya’s combination product for neurodegenerative diseases, COYA 302, an investigational combination biologic for subcutaneous administration, comprised of COYA 301 and CTLA4-Ig.
Lead Product(s): Coya 301,Abatacept
Therapeutic Area: Neurology Product Name: Coya 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Coya Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement March 20, 2023
Details:
Under the agreement, Coya granted Dr. Reddy’s an exclusive license to commercialize COYA 302, a proprietary co-pack kit containing combination of low dose interleukin-2 and CTLA-4 Ig (abatacept) for the treatment of Amyotrophic Lateral Sclerosis.
Lead Product(s): Interleukin 2,Abatacept
Therapeutic Area: Neurology Product Name: COYA 302
Highest Development Status: PreclinicalProduct Type: Large molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 06, 2023
Details:
Treatment with Orencia (abatacept) versus placebo displayed a strong but not statistically significant improvement in the primary endpoint of time to recovery as measured by day of hospital discharge.
Lead Product(s): Abatacept,Remdesivir
Therapeutic Area: Infections and Infectious Diseases Product Name: Orencia
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2022
Details:
U.S. Food and Drug Administration Approves Orencia® (abatacept) in Combination with a Calcineurin Inhibitor and Methotrexate for the Prevention of Acute Graft Versus Host Disease (aGvHD) in Patients Undergoing Hematopoietic Stem Cell Transplant Donor.
Lead Product(s): Abatacept,Methotrexate,Undisclosed
Therapeutic Area: Immunology Product Name: Orencia
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2021
Details:
Orencia is an immunomodulator that disrupts the continuous cycle of T-cell activation, psoriatic arthritis and juvenile idiopathic arthritis. Orencia targets unique and fundamental drivers of disease, resulting in improved efficacy and durability in seropositive RA patients.
Lead Product(s): Abatacept
Therapeutic Area: Immunology Product Name: Orencia
Highest Development Status: UndisclosedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2021
Details:
The ABA2 trial assessed the impact of Orencia on the prevention of severe aGvHD, when added to a standard GvHD prophylactic regimen administered to patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or mismatched donor.
Lead Product(s): Abatacept
Therapeutic Area: Immunology Product Name: Orencia
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 24, 2021
Details:
The ABA2 trial assessed the impact of Orencia on the prevention of severe aGvHD, when added to a standard GvHD prophylactic regimen administered to patients with hematologic malignancies receiving a stem cell transplant from an unrelated, HLA-matched or mismatched donor.
Lead Product(s): Abatacept
Therapeutic Area: Immunology Product Name: Orencia
Highest Development Status: Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 23, 2021
Details:
The three drugs are Janssen’s infliximab (Remicade), Bristol Myers Squibb’s (BMS) abatacept (Orencia) and AbbVie’s investigational late-stage drug Cenicriviroc (CVC).
Lead Product(s): Infliximab,Abatacept,Cenicriviroc
Therapeutic Area: Infections and Infectious Diseases Product Name: Remicade
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 16, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
